Imunon, Inc. Q3 FY2025 earnings call

Management highlighted progress with Imunon's proprietary IL-12 immunotherapy, IMNN-001, through the OVATION 3 pivotal phase III trial for newly diagnosed advanced ovarian cancer. The OVATION II study demonstrated overall survival benefit, and the company hosted a successful R&D day in New York City. OVATION 3 enrollment is surging, with nine patients randomized by end of October. The company accelerated engagement of a global CRO for study centers, and the MRD study has 25 patients randomized to date with plans to cap enrollment at 30 by mid-2026. Financially, the company has $5.3 million in cash, with R&D and G&A expenses reduced, and NASDAQ compliance closed.

Enrollment in OVATION 3 is ahead of plan, with full enrollment estimated by late 2028, potentially accelerable with financing. The company expects full approval based on successful interim analyses, leading to BLA filing and product availability for patients. Plans to leverage momentum from R&D day and scientific conferences to drive trial progress.

Challenges in the biotech capital markets environment, uncertainties related to regulatory approvals and interim analysis thresholds, and dependence on successful interim results and favorable benefit-risk profiles.

Q: David Bouth asked about how long macrophages produce IL-12 after IMNN-001 metabolism.

A: Khursheed Anwer explained the plasmid is internalized into cell nucleus, lasting days, producing IL-12.

Q: David Bouth asked about P-value and interim analysis thresholds.

A: Stacy Lindborg explained it's not a fixed P-value, involving complex operating characteristics and FDA-approved simulation results.

Q: James Malloy asked about pain management protocol.

A: Douglas Faller explained prophylactic analgesia is mandated in protocol to manage potential discomfort from infusions.

Q: James Malloy asked about EU regulatory approval and trial acceleration with funding.

A: Douglas Faller discussed EU approval expectations, and Stacy Lindborg mentioned potential trial acceleration with internal forecasts.

Q: Emily Bodnar asked about OVATION 2 update and OVATION 3 sites.

A: Stacy Lindborg and Douglas Faller discussed OVATION 2 results stability and overlap of sites between OVATION 2 and 3